MHL Is Holding Two Educational Symposia in June

HL e-Newsletter Series published on May 20, 2015
Download Transcript
MHL Is Holding Two Educational Symposia in June
Checkpoint Inhibitors Hold Great Promise for Treatment of Patients With Hodgkin Lymphoma

George Davatelis, PhDContributing Author

This June, Managing Hodgkin Lymphoma (MHL) is holding two accredited educational satellite symposia in conjunction with major medical conferences. One symposium will be held in concurrence with the Congress of the European Hematology Society (EHA) and the other in conjunction with the International Conference on Malignant Lymphoma (ICML). Both symposia will bring together world experts in lymphoma to discuss the latest key issues in the diagnosis and treatment of Hodgkin lymphoma (HL) and to review insights from ongoing research and key clinical trials.

Keeping up with the latest advances in the detection and management of HL is critically important for oncologists and allied health care providers (AHCP). This is because, although many advances have been made in frontline multiagent chemotherapy, and HL is deemed to be a highly curable disease, advanced HL remains a challenge for patients who do not achieve a complete remission (10% of patients) and for those who initially respond to therapy but experience a relapse (20%-30% of patients). So, these symposia are perfect fora to learn from some of the world’s experts on the latest advances in the battle against HL.

The first symposium, titled Key Issues in the Treatment of Lymphoma: the Role of CD30 in Diagnosis and Management, will be held on the opening day of the EHA Annual Congress, being held in Vienna, Austria, from June 11-14, 2015. Presentations and panel discussion will focus on the biology of CD30 and current data related to its focus as a key immunological target. 

The CD30 antigen was originally identified as a cell-surface marker of the malignant Hodgkin and Reed-Sternberg cells in HL. Although CD30 is found at different levels in B-cell lymphoma (BCL) and T-cell lymphoma (TCL) and in several reactive conditions, strong, homogeneous CD30 expression in most neoplastic cells is found mainly in 3 groups of lymphoid neoplasms: classical HL, anaplastic large-cell lymphomas (ALCL), and primary cutaneous CD30+ T-cell lymphoproliferative (PTCL) disorders. The detection of CD30 is a hallmark feature that is useful in the diagnosis of these conditions. The CD30 antigen has attracted substantial scientific interest as a therapeutic target for malignancies that express this cell-surface marker.

This symposium will be chaired by Anton Hagenbeek, MD, PhD, an esteemed hematologist-oncologist and professor of hematology at the University of Amsterdam. In 1979, Professor Hagenbeek was a member of the team that performed the first-ever autologous stem-cell transplant, in a young woman who had leukemia. He currently acts as chairperson of the Lunenburg Lymphoma Phase Biomarker Consortium, an international group studying the application of biomarker analyses to clinical practice. 

The other faculty members are all renowned experts, themselves, including Stefano Pileri, MD, PhD, professor of pathologic anatomy at the Bologna University School of Medicine. Dr. Pileri is a member of the Fondazione Italiana Linfomi, with an active role in coordinating the data center of the group in Modena. He has participated in numerous clinical trials, which have primarily focused on indolent lymphoma, HL, and aggressive lymphoma in elderly patients. He will address advances in CD30 pathology.

Francesco d’Amore, MD, is a clinical professor in malignant lymphoproliferative diseases in the Department of Haematology at Aarhus University Hospital and is currently chairman of the Working Group on TCLs and a member of the Coordinating Committee of the Nordic Lymphoma Group. He will also be presenting and will discuss the evolving role of CD30 in BCL and TCL.

Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, has served as the principal investigator of more than 60 clinical trials and led the National Cancer Institute (NCI)-funded Specialized Programs of Research Excellence in lymphoma. He serves on the Scientific Advisory Board of the Lymphoma Research Foundation and is a member of the NCI Lymphoma Steering Committee. He will be the final faculty member of this symposium and will address the evolving role of CD30 in HL.

This accredited educational activity is designed to help scientists, researchers, hematologists, oncologists, and other AHCPs better understand the role of CD30 in HL and TCLs, and be able to identify the critical pathobiological features of CD30+ lymphoid neoplasms. The symposium’s presentations and panel discussion will describe the immunohistochemical assessment of CD30 in patients with HL and TCLs and correlate the results of those assessments to assist health care providers formulate and implement a treatment plan for patients with HL, PTCL, or ALCL, while becoming more familiar with recommended treatment sequencing that is evolving as a result of new data.

“Please join us for what is sure to be an informative and engaging symposium.”

Anton Hagenbeek, MD, PhD
Professor of Hematology
Academic Medical Center
University of Amsterdam

The second symposium, titled Contemporary Therapy for HL: Where Are We Now? will be held on June 16, in conjunction with the 13th annual ICML being held in Lugano, Switzerland. With the increased number of therapeutic options becoming available for the treatment of HL, it has become more important than ever to keep up with the latest developments. This accredited educational activity is designed to offer hematologists, oncologists, and other participants the latest therapeutic insights from current practice and ongoing clinical trials for the management of HL.

This symposium will be chaired by Franco Cavalli, Scientific Director, Oncology Institute of Sothern Switzerland (IOSI), and President of the ICML. Dr. Cavalli was instrumental in founding the IOSI, the ICML, and the International Extranodal Lymphoma Study Group. Dr. Cavalli was also the founding editor of Annals of Oncology. From 2006 to 2008, he was president of the Union for International Cancer Control. In addition to chairing the Contemporary Therapy for HL symposium, Dr. Cavalli will give an overview of the current landscape of treatment for HL and discuss new and novel approaches in HL. 

The other faculty for this event include Dr. Tim Illidge, professor of targeted therapy at the University of Manchester, who has published extensively and serves on the central steering group of the National Cancer Research Institute lymphoma group, has represented the United Kingdom at international workshops in lymphoma, and was awarded the Institute of Cancer Sciences researcher of the year in 2012. He will discuss optimal treatment approaches to frontline treatment of HL. It should be noted that both Drs. Cavelli and Illidge were part of the MHL expert interview series, “Global Perspectives in HL,” posted on the website ManagingHodgkinLymphoma.com

The final speaker at the ICML symposium will be Peter Borchmann, MD, the scientific secretary of the German Hodgkin Study Group (GHSG), Department of Internal Medicine at the University Hospital of Cologne, Germany. Dr. Borchmann is leader of the working group “Survivorship” within the GHSG and responsible for the development of clinical studies for advanced-stage patients. He will be discussing the changing treatment paradigms for relapsed refractory HL. 

“As participants, you will have the opportunity to share your professional experiences with us and engage in discussion related to current and future management of this disease…We look forward to what is sure to be an informative and engaging program.”

                                                                                    Franco Cavalli, MD, FRCP
President, ICML
Scientific Director, IOSI

We hope that you will be able to join us for these informative educational opportunities. Invitations and registration forms for both symposia are available on the ManagingHodgkinLymphoma.com website. If you are not able to attend either of the conferences, please check back here for highlights from both meetings. There will also be an e-publication covering the satellite symposia, which will be posted in July.


References:

  1. American Cancer Society. Survival rates for Hodgkin disease by stage. http://www.cancer.org/cancer/hodgkindisease/detailedguide/hodgkin-disease-survival-rates.
  2. De Leval L, Gaulard P. CD30+ lymphoproliferative disorders. http://www.haematologica.org/content/95/10/1627.
  3. Lymphoma Hub. http://www.lymphomahub.com/features/expert-profile.
  4. Lymphoma Hub. http://www.lymphomahub.com/about/stefano-luminari.
  5. Leukemia Research. http://cd30lymphoma.elsevierresource.com/faculty/francesco-damore.
  6. Cancer.Net. http://www.cancer.net//about-us/cancernet-editorial-board/associate-editors/anas-younes-md.
  7. Piana R. After a distinguished career, trailblazing Swiss oncologist remains devoted to addressing the global cancer challenge. http://www.ascopost.com/issues/june-10,-2013-supplement/after-a-distinguished-career,-trailblazing-swiss-oncologist-remains-devoted-to-addressing-the-global-cancer-challenge.aspx. Published June 10, 2013.
  8. The Christie NHS Foundation Trust. http://www.christie.nhs.uk/about-the-christie/whos-who/our-consultants/tim-illidge.aspx.
  9. Leukemia Research. http://cd30lymphoma.elsevierresource.com/faculty/peter-borchmann.
Last modified: July 6, 2015

Managing HL would like to recognize and thank Merck & Co., Inc., Seattle Genetics, and Takeda Oncology for their educational support of ManagingHodgkinLymphoma.com

©2017 MediCom Worldwide, Inc. All rights reserved